SymBiosis Capital Partners, LLC 13F Holdings · Q1 2026
SymBiosis Capital Partners, LLC reported 6 securities worth $52.77M in its SEC 13F filing for Q1 2026 (period ended 2026-03-31). Top holdings: EVMN (55.80%), IVA (24.76%), WVE (10.30%). Among its top 25 positions this quarter: 1 new, 3 trimmed, 6 exited.
| Rank | Ticker | Company | Value | % Portfolio | Shares | Action |
|---|---|---|---|---|---|---|
| 1 | EVMN | Evommune, Inc. | $29.4M | 55.80% | 1.3M | Hold |
| 2 | IVA | Inventiva S.A. | $13.1M | 24.76% | 2.4M | Trimmed |
| 3 | WVE | Wave Life Sciences Ltd. | $5.4M | 10.30% | 750,000 | New |
| 4 | RANI | Rani Therapeutics Holdings, Inc. | $2.7M | 5.11% | 3.7M | Trimmed |
| 5 | CLNN | Clene Nanomedicine Inc. | $2.1M | 4.03% | 431,094 | Trimmed |
| 6 | AARD | Aardvark Therapeutics, Inc. | $0 | 0.00% | 0 | Exited |
| 7 | AMPG | Aldeyra Therapeutics Inc | $0 | 0.00% | 0 | Exited |
| 8 | GBIO | Generation Bio Co | $0 | 0.00% | 0 | Exited |
| 9 | NUVB | Nuvation Bio Inc | $0 | 0.00% | 0 | Exited |
| 10 | PGEN | Precigen Inc | $0 | 0.00% | 0 | Exited |
| 11 | SRZNW | Surrozen, Inc. | $2,400 | 0.00% | 150,000 | Hold |
| 12 | VSTM | Verastem Inc | $0 | 0.00% | 0 | Exited |
Source: SEC Form 13F filings · as of 2026-03-31
Every position in this 13F-HR, with its change from the prior quarter.
13F holdings, latest quarter
SourceSEC EDGAR13F-HR